|
|
【TMCLIFE 0101 交流专区】TMC生命科学
[复制链接]
|
|
|
发表于 28-3-2020 08:49 AM
|
显示全部楼层
Entitlement subject | Final Dividend | Entitlement description | Single-Tier Final Dividend of 0.2013 sen per Ordinary Share | Ex-Date | 06 Mar 2020 | Entitlement date | 09 Mar 2020 | Entitlement time | 5:00 PM | Financial Year End | 31 Aug 2019 | Period |
| | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Payment Date | 25 Mar 2020 | a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers | 09 Mar 2020 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| | c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units)
(If applicable) |
| | Entitlement indicator | Currency | Announced Currency | Malaysian Ringgit (MYR) | Disbursed Currency | Malaysian Ringgit (MYR) | Entitlement in Currency | Malaysian Ringgit (MYR) 0.0020 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 28-3-2020 09:18 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | VARIANCE OF UNAUDITED RESULTS AS ANNOUNCED ON 23 OCTOBER 2019 AND THE AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 AUGUST 2019 | 1. INTRODUCTION
The Board of Directors of the Company wishes to announce that the Company had on 24 October 2019 submitted its unaudited results for the year ended 31 August 2019 (“4Q FYE 2019’’) to Bursa Malaysia Securities Berhad (“Bursa Securities’’).
2. DEVIATION BETWEEN UNAUDITED RESULTS AND THE AUDITED RESULTS
In compliance with Paragraph 9.19(35) of the Main Market Listing Requirements of Bursa Securities, the Company wishes to inform that the deviation in results of more than 10% between the profit after tax attributable to owners of the Company as announced in 4Q FYE 2019 results on 24 October 2019 and the audited financial statements for the financial year ended 31 August 2019 (“AFS 2019”) was mainly due to the accounting for additional deferred tax liability that arose due to the change in the rate of Real Property Gains Tax from 5% to 10%. The deviation is reconciled and explained as below:
| Group | Variance |
| 4Q FYE 2019 | AFS 2019 | Amount | Percentage |
| RM’000 | RM’000 | RM’000 | % | Profit attributable to: |
|
|
|
| Owners of the Company | 28,096 | 20,919 | 7,177 | 26% |
|
|
|
|
| Total comprehensive income |
|
|
|
| attributable to: |
|
|
|
| Owners of the Company | 28,093 | 20,916 | 7,177 | 26% |
Reconciliation of deviation | Group |
| RM’000 | Profits attributable to owners of the Company |
| as per 4Q FYE 2019 | 28,096 |
|
| Additional deferred tax liability | (7,177) | Profits attributable to owners of the Company |
| as per AFS 2019 (Audited) | 20,919 |
|
| Total comprehensive income attributable to |
| owners of the Company as per 4Q FYE 2019 | 28,093 |
|
| Additional deferred tax liability | (7,177) | Total comprehensive income attributable to |
| owners of the Company as per AFS 2019 (Audited) | 20,916 |
The Group completed the acquisition of BB Waterfront Sdn. Bhd. (“BBWF”) in June 2015. The acquisition of BBWF was accounted for as an acquisition of business in accordance with the requirements of MFRS 3. At the Group level, the freehold land of BBWF was measured at fair value and a corresponding deferred tax liability was recorded to account for the difference between the fair value and the book value. The deferred tax liability was computed using the Real Property Gains Tax Rate of 5%.
The variance above is solely due to accounting for additional deferred tax liability that arose due to the change in the rate of Real Property Gains Tax from 5% to 10%. The Board was informed by our external auditors in December 2019 of the requirements to make this adjustment.
This adjustment is made to comply with the requirements of MFRS 112. It has no impact on the Group’s business operations, cash flows and the ability to distribute dividends.
This announcement is dated 18 December 2019. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3010568
|
|
|
|
|
|
|
|
|
|
|
|
发表于 9-4-2020 07:35 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Nov 2019 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | Three Months | Three Months | Three Months | Three Months | 01 Sep 2019
To | 01 Sep 2018
To | 01 Sep 2019
To | 01 Sep 2018
To | 30 Nov 2019 | 30 Nov 2018 | 30 Nov 2019 | 30 Nov 2018 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 52,534 | 0 | 52,534 | 0 | | 2 | Profit/(loss) before tax | 10,665 | 0 | 10,665 | 0 | | 3 | Profit/(loss) for the period | 7,953 | 0 | 7,953 | 0 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 7,953 | 0 | 7,953 | 0 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.46 | 0.00 | 0.46 | 0.00 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.4400 | 0.4400
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 10-4-2020 08:27 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | THOMSON HOSPITALS SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF TMC LIFE SCIENCES BERHAD - ACCEPTANCE OF NON-REVOLVING LINE INDUSTRIAL HIRE PURCHASE OF UP TO RM90.0 MILLION FROM OCBC BANK (MALAYSIA) BERHAD | 1. INTRODUCTION
The Board of Directors of TMC Life Sciences Berhad (“TMCLS” or “the Company”) wishes to announce that its wholly-owned subsidiary, Thomson Hospitals Sdn. Bhd., has accepted a Non-Revolving Line Industrial Hire Purchase of up to RM90.0 million (“the Facility”) with OCBC Bank (Malaysia) Berhad (“the Bank”) on 13 January 2020 based on terms and conditions as contained in the Bank’s the Letter of Offer dated 16 August 2019 and Supplemental Letter of Offer dated 12 December 2019.
2. INFORMATION OF THE FACILITY Facility type and Amount:
| Non-Revolving Line Industrial Hire Purchase of up to RM90.0 million.
| Purpose of the Facility: | To hire the equipment/goods (as applicable) approved by the Bank.
| Securities to be provided:
| A corporate guarantee from TMCLS in favour of the Bank.
|
3. FINANCIAL EFFECT OF THE FACILITY
The Facility (when fully drawn) is expected to increase the gearing of the Group. For illustrative purposes, based on the audited consolidated financial statements of the Company for the financial year ended 31 August 2019, the Facility is expected to increase the gearing of the Group from 0.002 times to 0.12 times.
The Board of Directors of the Company does not envisage any specific risk associated with the acceptance of the Facility, apart from the financing costs.
4. INTERESTS OF DIRECTORS, SUBSTANTIAL SHAREHOLDERS AND PERSONS CONNECTED
None of the Directors and/or substantial shareholders of the Company and persons connected to them have any interest, direct or indirect, in the Facility.
5. DIRECTORS’ RECOMMENDATION
The Board of Directors, after careful deliberation, is of the opinion that the acceptance of the Facility is in the best interest of the Company and TMCLS Group.
This announcement is dated 14 January 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 1-6-2020 07:15 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
29 Feb 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | Three Months | Three Months | Six Months | Six Months | 01 Dec 2019
To | 01 Dec 2018
To | 01 Sep 2019
To | 01 Sep 2018
To | 29 Feb 2020 | 28 Feb 2019 | 29 Feb 2020 | 28 Feb 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 50,894 | 0 | 103,428 | 0 | | 2 | Profit/(loss) before tax | 8,632 | 0 | 19,297 | 0 | | 3 | Profit/(loss) for the period | 6,823 | 0 | 14,776 | 0 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 6,823 | 0 | 14,776 | 0 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.39 | 0.00 | 0.85 | 0.00 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.4500 | 0.4400
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 20-11-2020 09:32 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31 May 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | Three Months | Three Months | Nine Months | Nine Months | 01 Mar 2020
To | 01 Mar 2019
To | 01 Sep 2019
To | 01 Sep 2018
To | 31 May 2020 | 31 May 2019 | 31 May 2020 | 31 May 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 34,873 | 0 | 138,301 | 0 | | 2 | Profit/(loss) before tax | -4,555 | 0 | 14,742 | 0 | | 3 | Profit/(loss) for the period | -4,301 | 0 | 10,475 | 0 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | -4,301 | 0 | 10,475 | 0 | | 5 | Basic earnings/(loss) per share (Subunit) | -0.25 | 0.00 | 0.60 | 0.00 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.4400 | 0.4400
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 25-12-2020 08:48 AM
|
显示全部楼层
本帖最后由 icy97 于 15-5-2021 09:16 AM 编辑
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | One Month | One Month | Ten Months | Ten Months | 01 Jun 2020
To | 01 Jun 2019
To | 01 Sep 2019
To | 01 Sep 2018
To | 30 Jun 2020 | 30 Jun 2019 | 30 Jun 2020 | 30 Jun 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 15,105 | 0 | 153,406 | 0 | | 2 | Profit/(loss) before tax | 3,678 | 0 | 18,420 | 0 | | 3 | Profit/(loss) for the period | 2,800 | 0 | 13,275 | 0 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 2,800 | 0 | 13,275 | 0 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.16 | 0.00 | 0.76 | 0.00 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.17 | 0.00 | 0.17 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.4400 | 0.4400
|
Entitlement subject | Final Dividend | Entitlement description | Single-Tier Final Dividend of 0.1678 sen per Ordinary Share | Ex-Date | 04 Dec 2020 | Entitlement date | 07 Dec 2020 | Entitlement time | 5:00 PM | Financial Year End | 30 Jun 2020 | Period |
| | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Payment Date | 04 Jan 2021 | a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers | 07 Dec 2020 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| | c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units)
(If applicable) |
| | Entitlement indicator | Currency | Announced Currency | Malaysian Ringgit (MYR) | Disbursed Currency | Malaysian Ringgit (MYR) | Entitlement in Currency | Malaysian Ringgit (MYR) 0.0017 | |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 25-12-2020 08:48 AM
|
显示全部楼层
本帖最后由 icy97 于 25-10-2021 08:01 AM 编辑
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2020 |
| INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2020 | 30 Sep 2019 | 30 Sep 2020 | 30 Sep 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 50,827 | 0 | 50,827 | 0 | | 2 | Profit/(loss) before tax | 10,621 | 0 | 10,621 | 0 | | 3 | Profit/(loss) for the period | 7,784 | 0 | 7,784 | 0 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 7,784 | 0 | 7,784 | 0 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.45 | 0.00 | 0.45 | 0.00 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.4500 | 0.4400
|
Date of change | 31 Dec 2020 | Name | PROFESSOR EMERITUS DATO' DR. KHALID BIN ABDUL KADIR | Age | 72 | Gender | Male | Nationality | Malaysia | Designation | Chairman | Directorate | Non Independent and Non Executive | Type of change | Resignation | Reason | medical reason and personal interest | Details of any disagreement that he/she has with the Board of Directors | No | Whether there are any matters that need to be brought to the attention of shareholders | No |
QualificationsNo | Qualifications | Major/Field of Study | Institute/University | Additional Information |
Working experience and occupation | N/A | Family relationship with any director and/or major shareholder of the listed issuer | NIL | Any conflict of interests that he/she has with the listed issuer | NIL | Details of any interest in the securities of the listed issuer or its subsidiaries | TMC Life Sciences Berhad:- Direct interest: 500,000 Ordinary Shares (0.03%)- Indirect interest: 200,000 Ordinary Shares (0.01%) |
Date of change | 01 Jan 2021 | Name | DATO' SRI MOHD MOKHTAR BIN MOHD SHARIFF | Age | 63 | Gender | Male | Nationality | Malaysia | Type of change | Redesignation | Previous Position | Director | New Position | Chairman | Directorate | Independent and Non Executive |
QualificationsNo | Qualifications | Major/Field of Study | Institute/University | Additional Information | | 1 | Masters | Masters of Business Administration | Phoenix International University | | | 2 | Professional Qualification | Certificate of Legal Practice | Legal Profession Qualifying Board of Malaysia | | | 3 | Degree | Bachelor of Law (Hons) | University of Wolverhampton | |
Working experience and occupation | 1. Admitted as Advocate & Solicitors of High Court of Malaya on 13 September 2019.2. Director of Special Branch from September 2017 to May 2018. 3. Director Narcotics and Crime Investigation Department from April 2015 to September 2017. 4. Chief Police Officer of State of Johor from January 2008 to April 2015. 5. Deputy Chief Police Officer of State of Johor from March 2007 to January 2008. 6. Deputy Chief Police Officer of State of Pahang from April 2006 to March 2007. 7. Head of Special Branch, Kuala Lumpur from December 2004 to April 2006. 8. Police Attaché, Embassy of Malaysia, Bangkok from December 2002 to February 2004. 9. Staff Officer of Special Branch, Bukit Aman Headquarters from 1996 to 2002. 10. Assistant Police Attaché, Embassy of Malaysia, Bangkok from June 1987 to June 1996. 11. Staff Officer of Special Branch, Police Headquarters from April 1978 to June 1987. |
SUMMARY OF KEY FINANCIAL INFORMATION
31 Dec 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2020 | 31 Dec 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 48,794 | 0 | 99,621 | 0 | | 2 | Profit/(loss) before tax | 6,979 | 0 | 17,600 | 0 | | 3 | Profit/(loss) for the period | 5,401 | 0 | 13,185 | 0 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 5,401 | 0 | 13,185 | 0 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.31 | 0.00 | 0.76 | 0.00 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.4500 | 0.4400
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 24-11-2021 08:43 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2021 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2021 | 30 Sep 2020 | 30 Sep 2021 | 30 Sep 2020 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 52,681 | 50,827 | 52,681 | 50,827 | | 2 | Profit/(loss) before tax | 5,323 | 10,621 | 5,323 | 10,621 | | 3 | Profit/(loss) for the period | 4,046 | 7,784 | 4,046 | 7,784 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 4,046 | 7,784 | 4,046 | 7,784 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.23 | 0.45 | 0.23 | 0.45 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.4600 | 0.4500
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 1-4-2024 07:05 AM
|
显示全部楼层
本帖最后由 icy97 于 1-4-2024 07:07 AM 编辑
Date of change | 29 Jan 2024 | Name | DR HENG JUN LI MELVIN | Age | 41 | Gender | Male | Nationality | Singapore | Type of change | Redesignation | Previous Position | Non Executive Director | New Position | Group Chief Executive Officer | Directorate | Executive |
QualificationsNo | Qualifications | Major/Field of Study | Institute/University | Additional Information | | 1 | Masters | Masters of Business Administration | Frankfurt School of Finance & Management | | | 2 | Degree | Bachelor of Medicine and Bachelor of Surgery ("MBBS") | University of London, St Georges Hospital | | | 3 | Diploma | Graduate Diploma Occupational Medicine | National University of Singapore | |
Working experience and occupation | Thomson Medical Group Limited, Singapore1 December 2022 to presentExecutive Director and Group Chief Executive OfficerGleneagles Hospital, IHH Healthcare January 2021 to 31 October 2022 Chief Executive OfficerJuly 2019 to December 2020 Chief Operating OfficerSeptember 2017 to June 2019 AVP, Operations Mesh Bio Pte Ltd July 2018 to Present Co-Founder & Medical AdvisorMinistry of Health, Singapore August 2016 to January 2018 Medical AdvisorGlobal Health Byte Holdings Pte Ltd (UNO Technologies Pte Ltd) June 2016 to December 2018 Investor & Medical AdvisorOneCare Medical Pte Ltd August 2014 to September 2017 Equity PartnerGlobal Medical Concierge Pte Ltd January 2013 to June 2017 Co-FounderTan Tock Seng Hospital January 2013 to March 2015 Medical Doctor, RadiologyNational Health Service (United Kingdom) June 2009 to August 2011 Medical Doctor | Family relationship with any director and/or major shareholder of the listed issuer | Nil | Any conflict of interests that he/she has with the listed issuer | Nil | Details of any interest in the securities of the listed issuer or its subsidiaries | Nil |
| Remarks : | | Dr Heng Jun Li Melvin will assume the role of Acting Group Chief Executive Officer of the Company on 29 January 2024. |
ype | Announcement | Subject | OTHERS | Description | TMC Life Sciences Berhad ("the Company") - Suspension of Group Chief Executive Officer | On behalf of the Company, the Board of Directors ("the Board") wishes to announce that the Company has suspended the employment of Puan Wan Nadiah Binti Wan Mohd Abdullah Yaakob as the Group Chief Executive Officer (“GCEO”) of the Company and the Chief Executive Officer (“CEO”) of Thomson Hospitals Sdn. Bhd., resulting in the powers, authorities and functions vested in her as the GCEO and CEO to be suspended with effect from 29 January 2024 until further announcement by the Board.
The Board wishes to announce further that the Company will continue its business as usual and during the period of suspension, one of our Directors, Dr. Heng Jun Li Melvin, will be appointed as the Acting GCEO, who will temporarily assume the duties and functions of GCEO.
The Company shall announce further developments on the above matter as and when necessary.
This announcement is dated 29 January 2024. |
Type | Reply to Query | Reply to Bursa Malaysia's Query Letter - Reference ID | IQL-30012024-00001 | Subject | SUSPENSION OF GROUP CHIEF EXECUTIVE OFFICER | Description | TMC Life Sciences Berhad ("the Company") - Suspension of Group Chief Executive Officer | Query Letter Contents | We refer to your Company’s announcement dated 29 January 2024, in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:-
1) To clarify the circumstances/reasons leading to the suspension of Puan Wan Nadiah Binti Wan Mohd Abdullah Yaakob as the Group Chief Executive Officer.
2) To briefly clarify the next course of action to be taken by the Company arising from the suspension and to indicate the estimated timeline to resolve the matter. | With reference to the announcement made on 29 January 2024 and the query raised by Bursa Malaysia Securities Berhad by way of its letter of 30 January 2024, on behalf of the Company, the Board of Directors (“the Board”) wishes to clarify that the suspension of Puan Wan Nadiah Binti Wan Mohd Abdullah Yaakob (“Puan Wan Nadiah”) is to facilitate internal disciplinary process relating to allegations stated in a show cause letter issued to her on 29 January 2024. Puan Wan Nadiah has been given 7 days (up to 5 February 2024) to submit her written reply to the said show cause letter. If she requires more time, Puan Wan Nadiah may be granted an additional 7 days to submit her written reply. If submitted within the time permitted, her written reply to the show cause letter will then be considered and deliberated to determine whether the next course of action in the disciplinary process is necessary. Mindful of the proceedings applicable by law and considering that several factors usually determine and dictate the exact time frame involved, the Board is unable, at this juncture, to estimate the timeframe involved to resolve this matter.
The Board took the view that in light of the on-going disciplinary process, the outcome of which can only be determined at a later date as well as the confidentiality surrounding the allegations, immediate disclosure of the facts or circumstances regarding the suspension would prejudice the outcome of the disciplinary process. Furthermore, the facts of the matter are still in a state of flux and a more appropriate moment for disclosure is imminent. The Board wishes to assure Bursa Malaysia Securities Berhad that future announcement(s) will be made at the appropriate moment. The Board wishes to give further assurance that every step is taken to maintain this matter at its strictest confidentiality.
This announcement is dated 31 January 2024. |
SUMMARY OF KEY FINANCIAL INFORMATION
31 Dec 2023 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2022 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 93,783 | 73,341 | 186,221 | 145,212 | | 2 | Profit/(loss) before tax | 19,680 | 7,682 | 39,823 | 16,410 | | 3 | Profit/(loss) for the period | 14,524 | 5,490 | 29,664 | 11,718 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 14,524 | 5,490 | 29,664 | 11,718 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.83 | 0.32 | 1.70 | 0.67 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.5000 | 0.4900
|
Type | Announcement | Subject | OTHERS | Description | TMC LIFE SCIENCES BERHAD ("TMCLS" OR "THE COMPANY") - LETTER OF INTENT ENTERED BETWEEN THOMSON HOSPITALS SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF TMCLS AND ONCOCARE MEDICAL PTE LTD | The Board of Directors of TMCLS wishes to announce that Thomson Hospitals Sdn. Bhd. (“THSB”) a wholly-owned subsidiary of TMCLS had on 21 February 2024 entered into a Letter of Intent (“LOI”) with Oncocare Medical Pte Ltd (“OC Singapore”) to confirm THSB’s intention in exclusive negotiations towards a formal agreement between THSB and OC Singapore in regard to the provision of selected services to THSB in THSB’s operations of the Oncology Centre at Thomson Hospital Kota Damansara (“THKD”).
(Both THSB and OC Singapore to be collectively referred to as the “Parties” and individually as a “Party”)
Please refer to the attachment for the details of the announcement.
This announcement is dated 22 February 2024.
|
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3423519
|
|
|
|
|
|
|
|
|
|
|
|
发表于 1-4-2024 07:08 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | TMC Life Sciences Berhad ("the Company") - Suspension of Group Chief Executive Officer | On behalf of the Company and further to the announcement made on 29 January 2024, the Board of Directors (“the Board”) wishes to announce that a second show cause letter dated 29 March 2024 (“Second Show Cause Letter”) was issued to Puan Wan Nadiah Binti Wan Mohd Abdullah Yaakob (“Puan Nadiah”) that contains allegations that are different from the first show cause letter that was issued on 29 January 2024 (“First Show Cause Letter”).
The Audit and Risk Management Committee (“ARMC”) had carefully reviewed the written replies from Puan Nadiah to the First Show Cause Letter, whereby ARMC had found and concluded that the written replies were generally insufficient to answer the allegations stated in the First Show Cause Letter. The ARMC has reported its findings and conclusion to the Board.
Depending on the findings and conclusion from the ARMC to Puan Nadiah’s response to the allegations stated in the Second Show Cause Letter, the Board will proceed with the next phase of the disciplinary process against Puan Nadiah for the allegations made in the First Show Cause Letter and, if applicable, the Second Show Cause Letter.
The Board will make further announcements on this matter at the appropriate time.
This announcement is dated 29 March 2024. |
|
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
3338 
139
